Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220412 | 1.00 | SHBG (0.53) | SHBGCYP3A4PIK3R1PIK3CAHIF1A | |
| SCHEMBL12140987 | 1.00 | SHBG (0.53) | SHBGCYP3A4PIK3R1PIK3CAHIF1A | |
| SCHEMBL4227246 | 1.00 | SHBG (0.53) | SHBGCYP3A4PIK3R1PIK3CAHIF1A | |
| SCHEMBL15195626 | 0.90 | SHBG (0.59) | SHBGCYP3A4PIK3R1PIK3CAHIF1A | |
| SCHEMBL4228890 | 0.80 | SHBG (0.35) | SHBGCYP3A4 | |
| SCHEMBL11951200 | 0.80 | PIK3R1 (0.36) | SHBGCYP3A4PIK3R1PIK3CAHIF1A | |
| SCHEMBL20277845 | 0.79 | SHBG (0.40) | SHBGCYP3A4 | |
| SCHEMBL4234810 | 0.78 | SHBG (0.34) | SHBG | |
| SCHEMBL4233002 | 0.78 | SHBG (0.34) | SHBG | |
| SCHEMBL4234806 | 0.78 | SHBG (0.34) | SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465615-B1 | TRICYCLIC-BIS-ENONE DERIVATIVES AND METHODS OF USE THEREOF | DARTMOUTH COLLEGE (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8067465-B2 | Tricyclic-bis-enone derivatives and methods of use thereof | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100261930-A1 | Tricyclic-Bis-Enone Derivatives and Methods of Use Thereof | NIH - DEITR | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261930-A1 | Tricyclic-Bis-Enone Derivatives and Methods of Use Thereof | PTGES, PTGES2, TBXAS1 | SHBG 4263/4885CYP3A4 789/4885PIK3R1 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.